Regulatoriskt pressmeddelande

Resolutions passed at the Annual General Meeting

Company announcement
Orphazyme A/S
No. 8/2023
Ole Maaløes Vej 3
DK-2200 Copenhagen N

www.orphazyme.com
Company Registration No. 32266355

Copenhagen, Denmark, May 17, 2023 – Orphazyme A/S (ORPHA.CO) (the “Company”), today held its Annual General Meeting, at which the Annual General Meeting:

Financial year 2022

Took note of the Board of Directors’ report on the Company’s activities in the past financial year;
Adopted the Company’s annual report for 2022
Adopted that the profit related to the financial year 2022 is carried forward
Approved the remuneration report for 2022 (advisory vote)
Approved the remuneration of the Board of Directors for 2023

Discharge of liability

Granted discharge of liability to the Board of Directors and the Executive Management in relation to the annual report for 2022

Composition of the Board of Directors

Bo Jesper Hansen, John Sommer Schmidt and Anders Fink Vadsholt withdrew their candidacies as members of the Board of Directors
Michael Hove, Jakob Bendtsen and Jakob Have were elected as new members of the Board of Directors
Re-elected EY Godkendt Revisionspartnerselskab as the Company’s auditor in accordance with the recommendation from the Audit Committee
After the Company’s Annual General Meeting was held, the Board of Directors constituted itself by appointing Michael Hove as Chairman

An overview of the qualifications and competencies of the new members of the Board of Directors is attached to this announcement.

Proposals by the Board of Directors

Adopted to renew the current authorization to the Board of Directors to acquire treasury shares
The proposal to adopt a revised remuneration policy was withdrawn

For additional information, please contact

Orphazyme A/S

Michael Hove, Chairman of the board +45 28 12 66 09

Attachments